Work

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy

Year: 2026

Type: article

Abstract: AIM: To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC). METHODS: Patients with cCSC were classified into bevacizumab and brolucizumab group. The proportion of complete resolution of subretinal fluid (SRF), best-corrected visual acuity (BCVA), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) were compared between the two groups. RESULTS: A total of 40 eyes from 40 patients with aged 34-59y were enrolled in the study. Twenty eyes in bevacizumab group (17 males) and 20 eyes (18 males) in brolucizumab group. Comparing the proportion of complete resolution of SRF, the brolucizumab group was statistically significantly higher than the bevacizumab group (P<0.05). In 1mo, CMT was significantly reduced in the brolucizumab group compared to the bevacizumab group (265±69 vs 319±70 μm; P=0.021). However, there was no significant difference in CMT between the two groups at 2 and 3mo (P>0.05). CONCLUSION: Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.

Source: International Journal of Ophthalmology

DOI: 10.18240/ijo.2026.02.14

Authors: Jung Yeon Joo, Seong Taeck Kim

Institutions: Chosun University, Chosun University Hospital

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,800